Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.07 (-8.12%)
Close on Nov 12, 2026Market cap $285.72MP/E –Yield 0.00%
Allogene Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Allogene Therapeutics's profit margin for the twelve months ending Dec 31, 2024 was -1170863.6%. For fiscal 2024 it was -1170863.6%, against -344489.5% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -1170863.6% | −826374.2 |
| FY2023 | Dec 31, 2023 | -344489.5% | −126275.4 |
| FY2022 | Dec 31, 2022 | -218214.1% | −218054.5 |
| FY2021 | Dec 31, 2021 | -159.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -919.8% | +359225.7 |
| Q1 FY2024 | Mar 31, 2024 | -295454.5% | +37772.1 |
| Q4 FY2023 | Dec 31, 2023 | -408466.7% | −34332.1 |
| Q3 FY2023 | Sep 30, 2023 | -283122.7% | +28884.7 |
| Q2 FY2023 | Jun 30, 2023 | -360145.5% | −234692.3 |
| Q1 FY2023 | Mar 31, 2023 | -333226.7% | −131670.3 |
| Q4 FY2022 | Dec 31, 2022 | -374134.6% | −374134.7 |
| Q3 FY2022 | Sep 30, 2022 | -312007.4% | −152444.1 |
| Q2 FY2022 | Jun 30, 2022 | -125453.1% | +35765.1 |
| Q1 FY2022 | Mar 31, 2022 | -201556.4% | −201470.3 |
| Q4 FY2021 | Dec 31, 2021 | 0.1% | – |
| Q3 FY2021 | Sep 30, 2021 | -159563.3% | – |
| Q2 FY2021 | Jun 30, 2021 | -161218.2% | – |
| Q1 FY2021 | Mar 31, 2021 | -86.1% | – |
See a number that looks wrong?